In lung cancer, CTRP6 promotes tumor proliferation and metastasis, while its knockdown induces ferroptosis via the xCT/GPX4 axis through SOCS2 ubiquitination and degradation [51], suggesting that targeting CTRP6 could sensitize tumors to ferroptosis-based therapies. The gene discussed is GPX4; the disease is neoplasm.